Biex To Educate Clinicians/Payers On SalEst Cost Benefits Prior To Roll-Out
This article was originally published in The Gray Sheet
Biex' 40-member sales and clinical support organization is preparing for the launch of the SalEst salivary estriol test in the U.S. with a six-week education program aimed at physicians and payers on the utility of the product as an aid in identifying women at risk for preterm labor and delivery.
You may also be interested in...
Biex, Inc. plans to relaunch its salivary estriol test for detecting pre-term labor (PTL) with a retooled business strategy after experiencing difficulties in its initial attempts to gain sufficient reimbursement coverage
Amunix’s XTEN technology for half-life extension and precise drug delivery has been used by multiple partners over the past 15 years, but now the firm is building its own cancer therapy pipeline.